Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CYTK Stock Summary
Top 10 Correlated ETFs
CYTK
In the News
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
Cytokinetics: CEO Talks Down Buyout Prospects
Cytokinetics: CEO Talks Down Buyout Prospects
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.
Cytokinetics to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March:
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.45 per share a year ago.
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve the quality of life of all human beings.
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.
Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
Previously recommended "Sell" on Cytokinetics; Aficamten's SEQUOIA-HCM data outperformed expectations, necessitating reevaluation. Aficamten revealed possibly improved efficacy and safety compared to Camzyos, implying that it could become a blockbuster treatment in HCM. CYTK's M&A appeal surged post-data, despite a dip after Novartis cooled acquisition talks; the current market cap suggests upside potential.
Cytokinetics stock plunges as Novartis retreats from merger talks
Cytokinetics stock plunged more than 16% Thursday to $84.95 after talks reportedly broke down with potential potential buyer Novartis AG (ADR) (NYSE:NVS). Shares of the biopharmaceutical company have more than doubled since the end of October on speculation of a deal, and on Wednesday the stock closed at $101.63 on speculation that a deal would go through.
CYTK Financial details
CYTK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.47 | 0.87 | 0.92 | 1.05 | 0.08 | |
Net income per share | -2.59 | -2.54 | -3.15 | -4.48 | -5.45 | |
Operating cash flow per share | -1.58 | 0.14 | -1.85 | -3.33 | -4.29 | |
Free cash flow per share | -1.62 | -0.03 | -2.49 | -3.46 | -4.31 | |
Cash per share | 3.91 | 7.19 | 6.13 | 8.71 | 6.37 | |
Book value per share | -0.19 | 1.76 | 3.17 | -1.2 | -4 | |
Tangible book value per share | -0.19 | 1.76 | 3.17 | -1.2 | -4 | |
Share holders equity per share | -0.19 | 1.76 | 3.17 | -1.2 | -4 | |
Interest debt per share | 2.84 | 2.75 | 3.89 | 8.91 | 7.18 | |
Market cap | 610.87M | 1.34B | 3.5B | 4.12B | 8.06B | |
Enterprise value | 710.51M | 1.4B | 3.66B | 4.8B | 8.7B | |
P/E ratio | -4.1 | -8.17 | -14.46 | -10.22 | -15.31 | |
Price to sales ratio | 22.74 | 24.02 | 49.76 | 43.51 | 1.07K | |
POCF ratio | -6.72 | 149.93 | -24.59 | -13.74 | -19.45 | |
PFCF ratio | -6.53 | -635.76 | -18.31 | -13.24 | -19.38 | |
P/B Ratio | -55.85 | 11.83 | 14.37 | -38.14 | -20.86 | |
PTB ratio | -55.85 | 11.83 | 14.37 | -38.14 | -20.86 | |
EV to sales | 26.44 | 25.02 | 51.99 | 50.74 | 1.16K | |
Enterprise value over EBITDA | -7.64 | -15.76 | -19.69 | -15.34 | -17.97 | |
EV to operating cash flow | -7.82 | 156.18 | -25.69 | -16.02 | -21 | |
EV to free cash flow | -7.6 | -662.29 | -19.13 | -15.44 | -20.93 | |
Earnings yield | -0.24 | -0.12 | -0.07 | -0.1 | -0.07 | |
Free cash flow yield | -0.15 | 0 | -0.05 | -0.08 | -0.05 | |
Debt to equity | -12.44 | 1.23 | 1.11 | -6.94 | -1.64 | |
Debt to assets | 0.47 | 0.26 | 0.32 | 0.74 | 0.77 | |
Net debt to EBITDA | -1.07 | -0.63 | -0.85 | -2.19 | -1.33 | |
Current ratio | 8.98 | 15.2 | 7.45 | 9.4 | 6.12 | |
Interest coverage | -3.61 | -2.43 | -6.35 | -6.34 | -8.6 | |
Income quality | 0.75 | -0.07 | 0.66 | 0.77 | 0.79 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | -0.04 | |
Sales general and administrative to revenue | 1.47 | 0.95 | 1.37 | 1.88 | 23.06 | |
Research and developement to revenue | 3.21 | 1.74 | 2.27 | 0.07 | 42.26 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | -1.24 | 0.34 | 0.04 | 0 | |
Capex to revenue | -0.1 | -0.2 | -0.69 | -0.12 | -0.19 | |
Capex to depreciation | -2.03 | -6.04 | -21.47 | -1.95 | -0.12 | |
Stock based compensation to revenue | 0.4 | 0.32 | 0.38 | 0.51 | 9.57 | |
Graham number | 3.33 | 10.03 | 15 | 11.01 | 22.16 | |
ROIC | -0.92 | -0.47 | -0.33 | -0.43 | -1.34 | |
Return on tangible assets | -0.51 | -0.31 | -0.29 | -0.4 | -0.64 | |
Graham Net | -1.25 | 0.69 | -1.47 | -3.79 | -6.16 | |
Working capital | 207.73M | 443.02M | 463.81M | 710.57M | 525.37M | |
Tangible asset value | -10.94M | 113.38M | 243.86M | -107.9M | -386.32M | |
Net current asset value | -67M | 53.8M | -61.78M | -327.49M | -582.59M | |
Invested capital | -12.44 | 1.23 | 1.11 | -6.94 | -1.64 | |
Average receivables | 5.97M | 4.79M | 28.12M | 25.98M | 715K | |
Average payables | 5.96M | 8.11M | 14.57M | 23.35M | 23.56M | |
Average inventory | -3.39M | -2.21M | -28.12M | -25.98M | -73.5K | |
Days sales outstanding | 70.14 | 28.9 | 268.56 | 0.57 | 62.19 | |
Days payables outstanding | 34.58 | 30.31 | 48.12 | 38.82 | 660.11 | |
Days of inventory on hand | 0 | -16.64 | -118.26 | -0.22 | 0 | |
Receivables turnover | 5.2 | 12.63 | 1.36 | 643.46 | 5.87 | |
Payables turnover | 10.55 | 12.04 | 7.58 | 9.4 | 0.55 | |
Inventory turnover | 0 | -21.93 | -3.09 | -1.64K | 0 | |
ROE | 13.63 | -1.45 | -0.99 | 3.73 | 1.36 | |
Capex per share | -0.05 | -0.17 | -0.64 | -0.13 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.02 | 0.05 | 0.01 | 0 | 0.02 | |
Net income per share | -1.39 | -1.36 | -1.34 | -1.35 | -1.38 | |
Operating cash flow per share | -1.04 | -1.29 | -1.27 | -1 | -0.75 | |
Free cash flow per share | -1.07 | -1.29 | -1.28 | -1 | -0.75 | |
Cash per share | 8.28 | 6.98 | 5.91 | 5.61 | 6.21 | |
Book value per share | -1.14 | -2.41 | -3.48 | -4.57 | -3.9 | |
Tangible book value per share | -1.14 | -2.41 | -3.48 | -4.57 | -3.9 | |
Share holders equity per share | -1.14 | -2.41 | -3.48 | -4.57 | -3.9 | |
Interest debt per share | 8.1 | 8.02 | 7.96 | 7.94 | 6.59 | |
Market cap | 4.33B | 3.35B | 3.12B | 2.83B | 8.27B | |
Enterprise value | 5.02B | 4B | 3.8B | 3.48B | 8.91B | |
P/E ratio | -8.24 | -6.47 | -6.07 | -5.47 | -15.1 | |
Price to sales ratio | 2.21K | 725.95 | 3.6K | 7.49K | 4.95K | |
POCF ratio | -44.11 | -27.39 | -25.64 | -29.42 | -111.72 | |
PFCF ratio | -42.72 | -27.3 | -25.49 | -29.35 | -111.6 | |
P/B Ratio | -40.14 | -14.62 | -9.38 | -6.45 | -21.41 | |
PTB ratio | -40.14 | -14.62 | -9.38 | -6.45 | -21.41 | |
EV to sales | 2.56K | 866.56 | 4.39K | 9.2K | 5.33K | |
Enterprise value over EBITDA | -41.41 | -33.86 | -33 | -30.14 | -73.61 | |
EV to operating cash flow | -51.08 | -32.69 | -31.23 | -36.16 | -120.39 | |
EV to free cash flow | -49.46 | -32.58 | -31.05 | -36.08 | -120.27 | |
Earnings yield | -0.03 | -0.04 | -0.04 | -0.05 | -0.02 | |
Free cash flow yield | -0.02 | -0.04 | -0.04 | -0.03 | -0.01 | |
Debt to equity | -6.94 | -3.28 | -2.25 | -1.71 | -1.64 | |
Debt to assets | 0.74 | 0.84 | 0.96 | 1.01 | 0.77 | |
Net debt to EBITDA | -5.65 | -5.49 | -5.91 | -5.62 | -5.31 | |
Current ratio | 9.4 | 9.05 | 8.94 | 7.22 | 6.12 | |
Interest coverage | -7.81 | -9.4 | -9.13 | -8.74 | -7.47 | |
Income quality | 0.71 | 0.93 | 0.95 | 0.74 | 0.54 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.03 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 27.58 | 10.77 | 45.82 | 106.11 | 26.38 | |
Research and developement to revenue | 3.37 | 0.46 | 1 | 1 | 47.03 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0 | 0.01 | 0 | 0 | |
Capex to revenue | -1.64 | -0.09 | -0.83 | -0.58 | -0.05 | |
Capex to depreciation | -1.93 | -0.22 | -0.39 | -0.12 | -0.01 | |
Stock based compensation to revenue | 6.9 | 3.29 | 21.53 | 49.51 | 11.65 | |
Graham number | 5.98 | 8.58 | 10.25 | 11.77 | 11.01 | |
ROIC | -0.16 | -0.19 | -0.22 | -0.27 | -0.34 | |
Return on tangible assets | -0.13 | -0.15 | -0.16 | -0.17 | -0.17 | |
Graham Net | -3.6 | -4.78 | -5.71 | -6.66 | -6 | |
Working capital | 710.57M | 605.41M | 520.96M | 483.69M | 525.37M | |
Tangible asset value | -107.9M | -229.02M | -333.12M | -438.8M | -386.32M | |
Net current asset value | -327.49M | -438.21M | -526.44M | -618M | -582.59M | |
Invested capital | -6.94 | -3.28 | -2.25 | -1.71 | -1.64 | |
Average receivables | 1.22M | 576.5K | 995.5K | 1.74M | 1.89M | |
Average payables | 20.02M | 21.48M | 14.96M | 13.18M | 17.65M | |
Average inventory | -73.5K | -576.5K | -995.5K | -1.74M | -1.25M | |
Days sales outstanding | 6.76 | 19.63 | 102.25 | 595 | 69.06 | |
Days payables outstanding | 30.73 | 19.67 | 13.59 | 15.04 | 305.55 | |
Days of inventory on hand | -0.18 | -1.14 | -1.07 | -2.73 | 0 | |
Receivables turnover | 13.31 | 4.59 | 0.88 | 0.15 | 1.3 | |
Payables turnover | 2.93 | 4.58 | 6.62 | 5.98 | 0.29 | |
Inventory turnover | -510.33 | -78.95 | -84.46 | -33.03 | 0 | |
ROE | 1.22 | 0.57 | 0.39 | 0.29 | 0.35 | |
Capex per share | -0.03 | 0 | -0.01 | 0 | 0 |
CYTK Frequently Asked Questions
What is Cytokinetics, Incorporated stock symbol ?
Cytokinetics, Incorporated is a US stock , located in South san francisco of Ca and trading under the symbol CYTK
Is Cytokinetics, Incorporated buy or a sell ?
8 stock analysts have 8 predictions with a medium analyst target price of $59.88. The lowest prediction is $45 and the highest is $75
What is CYTK stock prediction ?
What is Cytokinetics, Incorporated stock quote today ?
Cytokinetics, Incorporated stock price is $70.11 today.
Is Cytokinetics, Incorporated stock public?
Yes, Cytokinetics, Incorporated is a publicly traded company.